Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2026
Practical management of positive norovirus results from FilmArray® GI panel.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rybak Noémie, Bidet Philippe, Benhadid-Brahmi Yasmine, Cointe Aurélie, Dawoud Hosam, Gits-Muselli Maud, Baron Audrey, Bonacorsi Stéphane, Birgy André
Аннотация
BACKGROUND: On February the 7th 2024, BioFire® alerted users to a risk of false-positive norovirus results with the BioFire® FilmArray® Gastrointestinal Panel (BF-GIP) and recommended confirmatory testing.
OBJECTIVES: To assess the reliability of BF-GIP norovirus-positive results in children and develop a decision algorithm for managing potential false positives.
STUDY DESIGN: Between January and June 2025, all BF-GIP norovirus-positive samples were re-tested the same day using the GeneXpert® Norovirus assay (Cepheid®). BF-GIP cycle thresholds (Ct) values and melting curves were analyzed.
RESULTS: Of the 1007 BF-GIP performed, 131 were norovirus-positive and 127 were retested by the GeneXpert® Norovirus assay. Overall, 31.5 % (40/127) were discordant. Atypical melting curves (22/40, 55 %), high Ct values (> 25) or "N/A" results were strongly associated with discordance, while Ct ≤ 20 were highly predictive of concordance. Based on these metrics, 58 % of BF-GIP norovirus-positive results could be confidently confirmed or rejected without additional testing.
CONCLUSION: False norovirus-positive results by the BF-GIP are common. An algorithm integrating BF-GIP Ct values and melting curve analysis can reduce unnecessary retesting, streamline laboratory workflow and support accurate diagnosis in pediatric settings.
OBJECTIVES: To assess the reliability of BF-GIP norovirus-positive results in children and develop a decision algorithm for managing potential false positives.
STUDY DESIGN: Between January and June 2025, all BF-GIP norovirus-positive samples were re-tested the same day using the GeneXpert® Norovirus assay (Cepheid®). BF-GIP cycle thresholds (Ct) values and melting curves were analyzed.
RESULTS: Of the 1007 BF-GIP performed, 131 were norovirus-positive and 127 were retested by the GeneXpert® Norovirus assay. Overall, 31.5 % (40/127) were discordant. Atypical melting curves (22/40, 55 %), high Ct values (> 25) or "N/A" results were strongly associated with discordance, while Ct ≤ 20 were highly predictive of concordance. Based on these metrics, 58 % of BF-GIP norovirus-positive results could be confidently confirmed or rejected without additional testing.
CONCLUSION: False norovirus-positive results by the BF-GIP are common. An algorithm integrating BF-GIP Ct values and melting curve analysis can reduce unnecessary retesting, streamline laboratory workflow and support accurate diagnosis in pediatric settings.